Antibodies in late-stage clinical studies

The remarkable increase in the number of antibody therapeutics in late-stage clinical studies that occurred between 2010 and 2022 has been documented in the ‘Antibodies to watch‘ article series, which describes monoclonal antibodies in late-stage clinical studies (i.e., pivotal Phase 2, Phase 2/3 or Phase 3). All articles in the series were published in mAbs, and they are all freely available.

The table below is derived from data included in the latest article in the series, Antibodies to Watch in 2023, published in January 2023. The Antibody Society will update the data every quarter during 2023. Last table update: Nov 1, 2023.
Data for antibody therapeutic products that have advanced to regulatory review or approval in any country have been excluded from this table, but they are included in a searchable table that can be found here.

Biosimilar antibodies have been excluded from both tables.

Format and Fc modification data were compiled by Drs. Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.

Please cite our data as follows: The Antibody Society. Antibody therapeutics in late-stage clinical studies. (date accessed); www.antibodysociety.org/antibodies-in-late-stage-clinical-studies/

The table below is an interactive table that can be filtered based on multiple conditions. Please use the filtering criteria above the table and type in the search boxes in the header of each column.

Scroll right to see all the columns.

Drug Code(s)	INN	Target	Format	Specificity	Sequence source	Backbone	Light Chain	Conjugated/Unconjugated	Linker	Payload/Fusion	Mutations/Modifications	Phase of Clinical Development	Late-stage Clinical Study Indications	Therapeutic Area	Company	Licensee/Partner
MAA868, NOV-12	Abelacimab	Factor XI	Full-length antibody	Monospecific	Human	IgG1	lambda	Unconjugated			D265A P329A. Reduced effector functions	Phase 3	Venous thromboembolism (NCT05171075, NCT05171049), Atrial Fibrillation (NCT05712200)	Cardiovascular / hemostasis	Novartis	Anthos Therapeutics, MorphoSys
KN026	Anbenitamab	HER2, HER2 (biparatopic)	Full-length antibody	Bispecific	Humanized	IgG1; Hetero H	kappa (common light chain)	Unconjugated			Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)	Phase 2/3 (Phase 3 not yet recruiting)	Gastric (NCT05427383), breast cancer (NCT05838066, not yet recruiting)	Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Sanofi
CAEL-101, Ch mAb 11-1F4	Anselamimab	Amyloid	Full-length antibody	Monospecific	Chimeric	IgG1	kappa	Unconjugated			None found	Phase 3	Light chain (AL) amyloidosis (NCT04512235, NCT04504825)	Immune-mediated disorders	Caelum Biosciences	AstraZeneca
ARX788	Anvatabart opadotin	HER2	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Oxime (Non-cleavable linker)	Amberstatin 269 (Auroxime)	A114pAF (non-natural amino acid for site specific conjugation)	Phase 2/3	Breast cancer (NCT05426486)	Cancer	Ambrx	NovoCodex, Zhejiang Medicine Co. Ltd
I-131-BC8, Iomab-B	Apamistamab-Iodine (131I)	CD45	Full-length antibody	Monospecific	Murine	IgG1	kappa	RIC		I-131	None found	Phase 3	Acute myeloid leukemia (NCT02665065)	Cancer	Actinium Pharmaceuticals
SRK-015	Apitegromab	Myostatin	Full-length antibody	Monospecific	Human	IgG4	lambda	Unconjugated			S228P (hinge-stabilization)	Phase 3	Spinal muscular atrophy (NCT05156320)	Musculoskeletal disorders	Scholar Rock
RO7187807, MSTT1041A, RG6149, AMG282	Astegolimab	IL-33R	Full-length antibody	Monospecific	Human	IgG2	kappa	Unconjugated			None found	Phase 2/3	Chronic obstructive pulmonary disease (NCT05595642, NCT05878769)	Respiratory	Hoffmann-La Roche
REGN5713-5714-5715	Atisnolerbart, bremzalerbart, umesolerbart	Bet v1	Full-length antibody, mixture of 3	Mixture of 3 monospecific antibodies	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Seasonal allergic rhinitis (NCT04709575)	Immune-mediated disorders	Regeneron
SNDX-6352	Axatilimab	CSF-1R	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2 (pivotal)	Chronic Graft-versus-host-disease (NCT04710576),	Immune-mediated disorders	Syndax Pharmaceuticals, Inc	Incyte
FPA144	Bemarituzumab	FGFR2b	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 3	Gastric cancer/gastroesophageal junction adenocarcinoma (NCT05111626, NCT05052801)	Cancer	Amgen	Zai Lab
PB2452 (formerly MEDI2452)	Bentracimab	Ticagrelor	Fab	Monospecific	Human	Fab (IgG1 CH1)	lambda	Unconjugated			None found	Phase 3	Reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure (NCT04286438)	Cardiovascular / hemostasis	AstraZeneca	PhaseBio Pharmaceuticals, Inc., Alfasigma
NEOD001	Birtamimab	Amyloid	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Light chain (AL) amyloidosis (NCT04973137)	Immune-mediated disorders	Onclave Therapeutics Limited, subsidiary of Prothena
CC-93538, RPC4046; ABT-308, 13C5.5	Cendakimab	IL-13	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A (impair Fc effector functions)	Phase 3	Eosinophilic gastroenteritis (NCT05214768); Eosinophilic esophagitis (NCT04753697, NCT04991935)	Immune-mediated disorders	AbbVie	Bristol-Myers Squibb
JNJ-63723283	Cetrelimab	PD-1	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Bladder cancer (NCT04658862, NCT05714202)	Cancer	Janssen Research & Development, LLC	XOMA Corporation
ALD518; BMS-945429	Clazakizumab	IL-6	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			N297A (Fc-aglycosylated)	Phase 2/3 and Phase 3	Antibody-mediated rejection in kidney transplant recipients (NCT03744910); Atherosclerotic Cardiovascular Disease, End-stage kidney disease (NCT05485961)	Immune-mediated disorders	H. Lundbeck	Vitaeris Bio
MK-1654	Clesrovimab	RSV fusion protein	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half life extension)	Phase 2/3 and Phase 3	Reduction in incidence of respiratory syncytial virus infection (NCT04767373, NCT04938830)	Infectious disease	Merck Sharp & Dohme Corp.
GSK4069889, TSR-022	Cobolimab	TIM-3	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2/3	Non-small cell lung cancer (NCT04655976)	Cancer	GlaxoSmithKline
CDP-7657	Dapirolizumab pegol	CD40L	Fab	Monospecific	Humanized	IgG1	kappa	PEGylated		PEG	None found	Phase 3	Systemic lupus erythematosus (NCT04976322, NCT04294667)	Immune-mediated disorders	UCB	Biogen
DS-1062	Datopotamab deruxtecan	Trop-2	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Glycine-Glycine-Phenylalanine-Glycine (GGFG; Tetrapeptide-based cleavable linker)	DX-8951 (Topoisomerase I inhibitor)	None found	Phase 3	Non-small cell lung cancer (NCT05555732, NCT05215340, NCT04656652, NCT05687266); Breast cancer (NCT05374512, NCT05104866, NCT05629585)	Cancer	Daiichi-Sankyo
PF-06823859	Dazukibart	IFN-β	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A, G237A (impair Fc effector functions)	Phase 3	Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] (NCT05895786)	Immune-mediated disorders	Pfizer Inc.
GSK3511294	Depemokimab	IL-5	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half-life extension)	Phase 3	Hypereosinophilic syndrome (NCT05334368); Eosinophilic granulomatosis with polyangiitis (NCT05263934); Nasal polyps (NCT05274750, NCT05281523); Severe uncontrolled asthma with an eosinophilic phenotype (NCT05243680, NCT04719832, NCT04718103, NCT04718389)	Immune-mediated disorders	GlaxoSmithKline
AB154	Domvanalimab	TIGIT	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A (impair Fc effector functions)	Phase 3	Gastrointestinal tract adenocarcinoma (NCT05568095); Non-small cell lung cancer (NCT05211895, NCT05502237, NCT04736173)	Cancer	Arcus Biosciences	Gilead Sciences
RO5509554, RG7155	Emactuzumab	CSF-1R	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Tenosynovial giant cell tumor (NCT05417789)	Cancer	Hoffmann-La Roche	SynOx Therapeutics
KN046	Erfonrilimab	PD-L1, CTLA-4	VHH-Fc (tetravalent)	Bispecific	Chimeric, Humanized	IgG1; Hetero H; VH-VH-h-CH2-CH3 dimer	n/a	Unconjugated			Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)	Phase 3	Non-small-cell lung cancer (NCT04474119), Advanced Pancreatic Ductal Adenocarcinoma (NCT05149326)	Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd
MK-4280	Favezelimab	LAG-3	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Hodgkin lymphoma (NCT05508867); Colorectal cancer (NCT05600309, NCT05064059)	Cancer	Merck Sharp & Dohme Corp.
TJ202, MOR202, MOR03087	Felzartamab	CD38	Full-length antibody	Monospecific	Human	IgG1	lambda	Unconjugated			None found	Phase 3	Multiple myeloma (NCT03952091)	Cancer	MorphoSys AG	I-Mab Biopharma
REGN3767	Fianlimab	LAG-3	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization); E233P, F234V, L235A, G236del (reduced effector function)	Phase 2/3 and Phase 3	Melanoma (NCT05352672, NCT05608291); Non-small Cell Lung Cancer (NCT05785767, NCT05800015)	Cancer	Regeneron Pharmaceuticals	Sanofi
SCT-I10A, SCTI-10A	Finotonlimab	PD-1	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2/3 and Phase 3	Hepatocellular carcinoma (NCT04560894); Non-small-cell lung cancer (NCT04171284); Head and neck squamous cell carcinoma (NCT04146402)	Cancer	Sinocelltech Ltd
ABBV-383		BCMA, CD3		Bispecific	Human			Unconjugated				Phase 3 pending	Multiple myeloma (NCT06158841 not yet recruiting)	Cancer	AbbVie	Amgen
REGN2477	Garetosmab	Activin A	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Fibrodysplasia ossificans progressiva (NCT05394116)	Musculoskeletal disorders	Regeneron
ALXN1720	Gefurulimab	Complement C5, albumin	VHH (bivalent)	Bispecific	Humanized	VH - VH'	n/a	Unconjugated			None found	Phase 3	Generalized myasthenia gravis (NCT05556096)	Immune-mediated disorders	Alexion Pharmaceuticals, Inc.
GB226	Geptanolimab	PD-1	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2 (pivotal)	Cervical cancer (NCT03808857)	Cancer	Genor Biopharma Co., Ltd.
ACT017	Glenzocimab	Glycoprotein VI on platelets	Fab	Monospecific	Humanized	Fab (IgG1 CH1)	kappa	Unconjugated			None found	Phase 2/3	Acute ischemic stroke (NCT05070260, NCT05559398)	Cardiovascular / hemostasis	Acticor Biotech
BNT316, ONC-392	Gotistobart	CTLA-4	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half-life extension); S298A, E333A, K334A (enhanced ADCC)	Phase 3	Non-small cell lung cancer (NCT05671510)	Cancer	OncoC4, Inc	BioNTech
VAY736	Ianalumab	BLyS/BAFF/TACI/BCMA receptor	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 2/3 and Phase 3	Sjogren syndrome (NCT05350072, NCT05349214); Autoimmune hepatitis (NCT03217422); Lupus nephritis (NCT05126277); Systemic Lupus Erythematosus (NCT05624749, NCT05639114); Warm Autoimmune Hemolytic Anemia (wAIHA) (NCT05648968); Primary Immune Thrombocytopenia (ITP) (NCT05653349, NCT05653219)	Immune-mediated disorders	MorphoSys	Novartis
ANB019	Imsidolimab	IL-36R	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Generalized pustular psoriasis (NCT05352893, NCT05366855)	Immune-mediated disorders	AnaptysBio, Inc.
RO4905417, RG1512	Inclacumab	P-selectin (CD62)	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization); L235E (impair Fc effector function)	Phase 3	Vaso-occlusive crisis in sickle cell disease patients (NCT05348915, NCT04927247, NCT04935879)	Cardiovascular / hemostasis	Hoffmann-La Roche; Genmab	Global Blood Therapeutics
REGN3500, SAR440340	Itepekimab	IL-33	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Chronic obstructive pulmonary disease (NCT04751487, NCT04701983)	Respiratory	Regeneron	Sanofi
PF-04518600	Ivuxolimab	OX40	Full-length antibody	Monospecific	Human	IgG2	kappa	Unconjugated			None found	Phase 3	Advanced malignancies (NCT05059522)	Cancer	Pfizer Inc.
SI-B001	Izalontamab	EGFR, HER3	IgG-(scFv)2	Bispecific		IgG1-(scFv)2	kappa	Unconjugated			None found	Phase 2/3	Non-small cell lung cancer (NCT05020769)	Cancer	Biokin	Sichuan Baili Pharmaceutical Co. Ltd, SystImmune Inc.
AL001	Latozinemab	Sortilin	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			L234A, L235A, P331S (remove Fc effector functions)	Phase 3	Frontotemporal dementia (NCT04374136)	Neurological disorders	Alector	GlaxoSmithKline
ABBV-IMAB-TJC4, TJ011133, TJ133, TJC4	Lemzoparlimab	CD47	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Myelodysplastic Syndromes (MDS) (NCT05709093)	Cancer	I-Mab Biopharma Co. Ltd.	AbbVie
QGE031	Ligelizumab	IgE	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Food allergy (NCT05678959)	Immune-mediated disorders	Tanox	Novartis
REGN5458	Linvoseltamab	BCMA, CD3	Full-length antibody	Bispecific	Human	IgG4; Hetero H, cL	kappa	Unconjugated			Hetero HH: WT x H435R-Y436F (limits binding to Protein A, purification); HL-pairing: cL; both chains: E233P, F234V, L235A, G236del (Fc-silencing)	Phase 2 (potentially pivotal)	Multiple myeloma (NCT03761108, NCT05730036)	Cancer	Regeneron
BIIB059	Litifilimab	BDCA2	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 2/3 and Phase 3	Cutaneous lupus erythematosus (NCT05531565); Systemic lupus erythematosus (NCT05352919, NCT04961567, NCT04895241)	Immune-mediated disorders	Biogen
STRO-002	Luveltamab tazevibulin	FRα	Full-length antibody	Monospecific	Human	IgG1	kappa	ADC	Valine citrulline p-aminobenzyl carbamate linker functionalized with dibenzocyclooctyne (DBCO) (Cleavable linker)	SC209 (Hemiasterlin)	Y180pAMF, F404pAMF (non-natural amino acid for site specific conjugation)	Phase 2/3	Ovarian Cancer, Fallopian Tube Cancer (NCT05870748)	Cancer	Sutro Biopharma	Tasly Biopharmaceuticals Co., Ltd.
ONO-7913, Hu5F9-G4	Magrolimab	CD47	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Myelodisplastic syndromes (NCT04313881); Acute myeloid leukemia (NCT04778397, NCT05079230)	Cancer	Gilead Sciences	Ono Pharmaceutical Co
BA3011, HTBA3011, CAB-AXL-ADC	Mecbotamab vedotin	AXL receptor tyrosine kinase	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Valine citrulline (maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC); Cleavable linker)	MMAE	None found	Phase 2 (potentially pivotal)	Soft tissue and primary bone sarcoma (NCT03425279); Non-small Cell Lung Cancer (NCT04681131)	Cancer	BioAlta LLC	Himalaya Therapeutics
NN8765, IPH-2201, NNC141-0100	Monalizumab	NKG2A	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Squamous Cell Carcinoma of the Head and Neck (NCT04590963); Non-small Cell Lung Cancer (NCT05221840)	Cancer	Novo Nordisk	AstraZeneca; Innate Pharma
JNJ-80202135, M281	Nipocalimab	FcRn	Full-length antibody	Monospecific	Human	IgG1	lambda	Unconjugated			N297A (Fc-aglycosylated)	Phase 2/3 and Phase 3	Warm autoimmune hemolytic anemia (NCT04119050); Generalized myasthenia gravis (NCT05265273, NCT04951622) ; Polyradiculoneuropathy (NCT05327114)	Immune-mediated disorders	Janssen
CS1003	Nofazinlimab	PD-1	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Hepatocellular carcinoma (NCT04194775)	Cancer	Cstone Pharmaceuticals	EQRx
BCD-217 in combo with prolgolimab; BCD-145;	Nurulimab	CTLA-4	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Melanoma (NCT05732805, NCT05751928)	Cancer	Biocad
ZB012, XMAB5871	Obexelimab	CD19, Fc𝛄RIIb	Full-length antibody	Bispecific	Humanized	IgG1	kappa	Unconjugated			S267E, L328F (increase binding to FcγRIIb)	Phase 3	IgG4 Related Disease (NCT05662241); Warm Autoimmune Hemolytic Anemia (NCT05786573 not yet recruiting)	Immune-mediated disorders	Xencor	Zenas BioPharma Ltd; Amgen
BGB-A1217	Ociperlimab	TIGIT	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT04746924, NCT04866017)	Cancer	BeiGene
MEDI9447	Oleclumab	CD73	Full-length antibody	Monospecific	Human	IgG1	lambda1	Unconjugated			L234F, L235E, P331S (reduced effector function)	Phase 3	Non-small cell lung cancer (NCT05221840)	Cancer	AstraZeneca
L19TNF, L19(scFv)2-TNF	Onfekafusp alfa	Fibronectin extra-domain B	scFv fused with TNF	Monospecific	Human	scFv fused with TNF	kappa	Immunoconjugate		TNF	None found	Phase 3	Soft tissue sarcoma (NCT04650984)	Cancer	Philogen S.p.A.
Mab-B43.13	Oregovomab	CA125	Full-length antibody	Monospecific	Murine	IgG1	kappa	Unconjugated			None found	Phase 3	Ovarian cancer (NCT04498117)	Cancer	Quest PharmaTech Inc.	OncoQuest Pharmaceuticals, Inc.
JCT205, INBRX-109	Ozekibart	DR5	VHH-Fc (tetravalent)	Monospecific	Humanized	VHH-Fc (Fc IgG1)	n/a	Unconjugated			E233>del,L234>del, L235>del (reduced effector function: CDC and ADCC)	Phase 2 (pivotal)	Conventional Chondrosarcoma (NCT04950075)	Cancer	Inhibrx, Inc.	Transcenta Holding Limited
FG-3019	Pamrevlumab	Connective tissue growth factor	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Duchenne muscular dystrophy (NCT04632940, NCT04371666); Idiopathic pulmonary fibrosis (NCT04419558, NCT03955146); Pancreatic cancer (NCT03941093, NCT04229004)	Musculoskeletal disorders (secondary areas: Respiratory, Cancer)	FibroGen
EB05, NI-0101	Paridiprubart	Toll-like receptor 4	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			N325S, L328F (abrogates C1q and FcγRIII binding, increases FcγRII binding, retains FcγRI high affinity binding)	Phase 2/3	COVID-19-related acute respiratory distress syndrome (NCT04401475)	Respiratory	NovImmune SA	Edesa Biotech
IBI112	Picankibart	IL-23p19	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half life extension)	Phase 3	Psoriasis (NCT05645627)	Immune-mediated disorders	Innovent Biologics (Suzhou) Co. Ltd.
IMGN632	Pivekimab sunirine	CD123	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Alanine-Alanine (Cleavable linker)	DGN549 IGN	S442C (site-specific conjugation)	Phase 2 (pivotal)	Blastic plasmacytoid dendritic cell neoplasm (NCT03386513 CADENZA)	Cancer	ImmunoGen
MK-1308, AK107	Quavonlimab	CTLA-4	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Renal cell carcinoma (NCT04736706, NCT05899049)	Cancer	Akeso Biopharma	Merck Sharp & Dohme Corp.
LY3372993	Remternetug	Amyloid beta	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Alzheimer's Disease (NCT05463731)	Neurological disorders	Eli Lilly
SHR-1701	Retlirafusp alfa	PD-L1, TGF-β	Full-length fused with TGF-β receptor II	Bispecific	Human	IgG4	kappa	Immunoconjugate		TGF-β receptor II	S228P (hinge-stabilization)	Phase 2/3 and Phase 3	Cervical cancer (NCT05179239); Colorectal cancer (NCT04856787); Gastric or gastroesophageal junction cancer (NCT04950322); Non-small cell lung cancer (NCT05132413 not yet recruiting); Perioperative treatment of resectable gastric or gastroesophageal junction cancer (NCT05149807)	Cancer	Jiangsu HengRui Medicine Co., Ltd.	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
KHK4083, AMG451	Rocatinlimab	OX40	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Atopic dermatitis (NCT05398445, NCT05633355, NCT05651711, NCT05724199, NCT05704738, NCT05882877, NCT05899816)	Immune-mediated disorders	Kyowa Hakko Kirin	Amgen
TLX591, ATL-101, Lu-177-huJ591	Rosopatamab (177Lu-DOTA)	PSMA	Full-length antibody	Monospecific	Humanized	IgG1	kappa	RIC		Lu-177	None found	Phase 3 pending	Prostate cancer (NCT04876651 not yet recruiting)	Cancer	Telix Pharmaceuticals
F520	Rulonilimab	PD-1	Full-length antibody	Monospecific	Chimeric	IgG1	kappa	Unconjugated			N297A (Fc-aglycosylated); T250Q, M428L (half life extension)	Phase 2/3	Hepatocellular carcinoma (NCT05408221)	Cancer	Shandong New Time Pharmaceutical Co., LTD
PF-06801591	Sasanlimab	PD-1	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	Non-muscle invasive bladder cancer (NCT04165317)	Cancer	Pfizer
UB-421, dB4C7	Semzuvolimab	CD4	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			N297H (Fc-aglycosylated to remove Fc effector function)	Phase 3	HIV infection (NCT04406727 not yet recruiting)	Infectious disease	United Biopharma
UX143, BPS804, MOR05813	Setrusumab	Sclerostin	Full-length antibody	Monospecific	Human	IgG2	lambda	Unconjugated			None found	Phase 2/3 and Phase 3	Osteogenesis imperfecta (NCT05125809, NCT05768854)	Musculoskeletal disorders	Ultragenyx Pharmaceutical Inc	Mereo BioPharma
VIS649	Sibeprenlimab	APRIL	Full-length antibody	Monospecific	Humanized	IgG2	kappa	Unconjugated			None found	Phase 3	IgA nephropathy (NCT05248646; NCT05248659)	Immune-mediated disorders	Otsuka Pharmaceutical
AR-320, MEDI4893	Suvratoxumab	S. aureus 𝛂-toxin	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half life extension)	Phase 3	Ventilator Associated Pneumonia caused by Staph aureus (NCT05331885)	Infectious disease	AstraZeneca	Aridis
ABBV-399	Telisotuzumab vedotin	cMet	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Valine–citrulline (Cleavable linker)	MMAE	K222C T223del T225del K447del	Phase 3	Non-small cell lung cancer (NCT04928846)	Cancer	AbbVie
MTIG7192A, RO7092284, RG6058	Tiragolumab	TIGIT	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT04294810, NCT04513925, NCT04619797); Esophageal cancer (NCT04543617, NCT04540211)	Cancer	Genentech
AR-301, KBSA301	Tosatoxumab	S. aureus 𝛂-toxin	Full-length antibody	Monospecific	Human	IgG1	lambda	Unconjugated			None found	Phase 3	Ventilator-associated pneumonia caused by S. aureus (NCT03816956)	Infectious disease	Kenta Biotech Ltd	Aridis Pharmaceuticals, Serum AMR
MEDI3506	Tozorakimab	IL-33	Full-length antibody	Monospecific	Human	IgG1	lambda2	Unconjugated			None found	Phase 3	Chronic obstructive pulmonary disease (NCT05166889, NCT05158387, NCT05742802); Acute respiratory failure (NCT05624450)	Respiratory	AstraZeneca/MedImmune
IKS014, LCB14-0110, FS-1502, Trastuzumab mafodotin (not WHO assigned INN)		HER2	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	β-glucuronidase (BG; Cleavable linker	MMAF	C terminal CaaX sequence for site specific conjugation	Phase 3	Breast cancer (NCT05755048)	Cancer	LegoChem Biosciences, Inc.	IKSUDA Therapeutics, Shanghai Fosun Pharmaceutical Development Co, Ltd.
SHR-A1811	Trastuzumab rezetecan	HER2	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Undisclosed	Rezetecan	None found	Phase 3	Breast cancer (NCT05424835, NCT05814354)	Cancer	Jiangsu HengRui Medicine Co., Ltd.
MK-7684	Vibostolimab	TIGIT	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Non-small cell lung cancer (NCT04738487; NCT05298423; NCT05226598); Small cell lung cancer (NCT05224141); Melanoma (NCT05665595)	Cancer	Merck Sharp & Dohme Corp.
MGC018	Vobramitamab duocarmazine	B7-H3	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Valine-citrulline–seco (Cleavable linker)	Duocarmycin	None found	Phase 2/3	Prostate cancer (NCT05551117 TAMARACK)	Cancer	Macrogenics
AK111	Gumokimab	IL-17	Full-length antibody	Monospecific		IgG1	kappa	Unconjugated			None found	Phase 3	Plaque psoriasis(CTR20230111)	Immune-mediated disorders	Akesobio Australia Pty Ltd
SYN023 (mixture of CTB011 + CTB012)	Zamerovimab, mazorelvimab	Rabies virus spike glycoprotein	Full-length antibody, mixture of 2	Mixture of 2 monospecific antibodies	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Rabies (NCT04644484)	Infectious disease	Synermore Biologics Co. Ltd.
MK-2140	Zilovertamab vedotin	ROR1	Full-length antibody	Monospecific	Humanized	IgG1	kappa	ADC	Valine-citrulline (Maleimidocaproyl-valine-citrulline-para-aminobenzoate; Cleavable linker)	MMAE	None found	Phase 2/3	Diffuse large B-cell lymphoma (NCT05139017)	Cancer	Merck Sharp & Dohme LLC
COR-001	Ziltivekimab	IL-6	Full-length antibody	Monospecific	Human	IgG1	kappa	Unconjugated			M252Y, S254T, T256E (half life extension)	Phase 3	Atherosclerotic cardiovascular disease, chronic kidney disease (NCT05021835); Heart Failure (NCT05636176)	Cardiovascular / hemostasis	AstraZeneca	Novo Nordisk A/S
9MW0211		VEGF	Full-length antibody	Monospecific				Unconjugated				Phase 2/3	Wet age-related macular degeneration	Ophthalmic disorders	Mabwell (Shanghai) Bioscience Co., Ltd.	Apexigen
ABC008	Ulviprubart	KLRG1	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 2/3	Inclusion Body Myositis (NCT05721573)	Immune-mediated disorders	Abcuro, Inc.
ANX005		Complement C1q	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			None found	Phase 3	Guillain-Barré syndrome (NCT04701164)	Cardiovascular / hemostasis	Annexon Biosciences
APX003, BD0801, TK001, sevacizumab (not WHO assigned INN)	Suvemcitug	VEGF	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated				Phase 3	Ovarian cancer (NCT04908787)	Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	Apexigen
AZD5156	cilgavimab, sipavibart	SARS-CoV-2	Full-length antibody	Mixture of 2 monospecific antibodies		IgG1	kappa (cilgavimab), lambda (sipavibart)	Unconjugated			Long Acting Antibodies (LAAB); Reduce Fc effector function (L234F L235E P331S) and extend half-life ( M252Y S254T T256E)	Phase 3	Pre-exposure prophilaxis of COVID-19 (NCT05648110)	Infectious disease	AstraZeneca	RQ Biotechnology
BAT5906		VEGF	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 3	Neovascular (Wet) Age-related Macular Degeneration (NCT05439629)	Ophthalmic disorders	Bio-Thera Solutions
CBP-201	Rademikibart	IL-4Rα	Full-length antibody	Monospecific		IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 2 (pivotal)	Atopic dermatitis (NCT05017480)	Immune-mediated disorders	Suzhou Connect Biopharmaceuticals, Ltd.
CTX-009, ES104, TR009, NOV1501, ABL001		DLL4, VEGF	Full-length antibody	Bispecific				Unconjugated				Phase 2/3	Biliary tract cancers (NCT05506943)	Cancer	National OncoVenture	Compass Therapeutics, Inc., Elpiscience Biopharmaceuticals, ABL Bio Inc.
DP303c		HER2	Full-length antibody	Monospecific		IgG1	kappa	ADC	enzyme-based cleavable peptide-linker	MMAE	None found	Phase 3 pending	Breast cancer (NCT05901935 not yet recruiting)	Cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
E2814		Tau	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 2/3	Dominantly inherited Alzheimer's Disease (NCT05269394, NCT01760005)	Neurological disorders	Eisai Co., Ltd.
GMA-102, Glutazumab (not WHO assigned INN), GMA-105		GLP-1R	Full-length antibody	Monospecific	Humanized	IgG2		Immunoconjugate		GLP-1 peptide	None found	Phase 3	Type 2 diabetes (CTR20222558, CTR20211661)	Metabolic disorders	Gmax Biopharm Australia Pty Ltd
IAH0968		HER2	Full-length antibody	Monospecific				Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 2/3	Colorectal Cancer (NCT05673512)	Cancer	SUNHO（China）BioPharmaceutical CO., Ltd. or Beijing Sunho Pharmaceutical Co.
HP6H8, meplazumab		CD147	Full-length antibody	Monospecific	Humanized	IgG2		Unconjugated				Phase 2/3	COVID-19 (NCT05113784, NCT04586153, NCT05679479); post-COVID-19 (NCT05813587)	Infectious disease	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
IBI311		IGF-1R	Full-length antibody	Monospecific				Unconjugated				Phase 2/3	Thyroid Eye Disease (NCT05795621)	Immune-mediated disorders	Innovent Biologics, Inc
Kintuximab, gentuximab, cintuximab (not WHO assigned INN)		VEGFR2	Full-length antibody	Monospecific	Chimeric			Unconjugated				Phase 3	Advanced gastric or gastroesophageal junction adenocarcinoma (CTR20220815)	Cancer	GeneScience Pharmaceuticals Co., Ltd.	Changchun Jinsai Pharmaceutical Co., Ltd.
LMN-201		C. difficile exotoxin TcdB	VHH homodimers, mixture of 3	Mixture of 3 monospecific VHH homodimers		VHH homodimers		Unconjugated			None found	Phase 2/3 pending	Clostridioides difficile infection (NCT05330182 not yet recruiting)	Infectious disease	Lumen Bioscience, Inc.
MIL62		CD20	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 3	Neuromyelitis optica spectrum disorder (NCT05314010); Follicular lymphoma and marginal zone lymphoma (NCT04834024); Systemic Lupus Erythematosus (NCT05796206 not yet recruiting)	Cancer	Beijing Mabworks Biotech Co., Ltd.
MRG002		HER2	Full-length antibody	Monospecific	Humanized	IgG1		ADC	Valine-Citrulline (Cleavable linker)	MMAE	Hyperfucosylated (reduce Fc𝛾RIIIa binding/reduce ADCC)	Phase 2/3	Breast Cancer (NCT04924699)	Cancer	Shanghai Miracogen Inc.
MRG003		EGFR	Full-length antibody	Monospecific	Human	IgG1		ADC	Valine-Citrulline (Cleavable linker)	MMAE		Phase 3	Squamous Cell Carcinoma of the Head and Neck (NCT05751512)	Cancer	Shanghai Miracogen Inc.
AntiBKV, MTX-005, mAb129		BK virus	Full-length antibody	Monospecific	Human			Unconjugated				Phase 2/3	BK Viremia (NCT05769582)	Infectious disease	Memo Therapeutics AG
NNC0365-3769, Mim8		Factor IXa, Factor X	Full-length antibody	Bispecific	Human	IgG4		Unconjugated				Phase 3	Hemophilia A with or without inhibitors (NCT05306418, NCT05053139, NCT05685238, NCT05878938)	Cardiovascular / hemostasis	Novo Nordisk A/S
PM8002		PD-L1, VEGF	Full-length antibody	Bispecific		IgG1		Unconjugated			Fc silencing mutations (specific ones unknown); anti-PDL1 VHH fused to the antibody to become bispecific	Phase 2/3	Non-small Cell Lung Cancer (NCT05756972); Small Cell Lung Cancer (NCT05844150)	Cancer	Biotheus Inc.
RO7200220, RG6179		IL-6	Full-length antibody	Monospecific	Humanized	IgG2		Unconjugated				Phase 3	Uveitic macular edema (NCT05642325, NCT05642312)	Ophthalmic disorders	Hoffmann-La Roche
RO7204239, GYM329, RG6237		Myostatin	Full-length antibody	Monospecific	Humanized	IgG1		Unconjugated			Specific mutations not found; engineered for selective and enhanced binding to the human FcγRIIb and for stronger affinity to FcRn in acidic pH conditions	Phase 2/3	Spinal muscular atrophy (NCT05115110)	Musculoskeletal disorders	Chugai	Roche
SSGJ-601, 601		VEGF	Full-length antibody	Monospecific	Humanized			Unconjugated				Phase 3	Branch retinal vein occlusion (NCT05520177)	Ophthalmic disorders	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
SSGJ-608, 608		IL-17A	Full-length antibody	Monospecific				Unconjugated				Phase 3	Psoriasis (NCT05536726)	Immune-mediated disorders	3SBio	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
TNM002		Tetanus toxin	Full-length antibody	Monospecific	Human			Unconjugated				Phase 3	Tetanus (NCT05664750)	Infectious disease	Zhuhai Trinomab Biotechnology Co Ltd.	China Medical System Holdings Limited
ZB001, VRDN-001, IMGN164, AVE1642		IGF-1R	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			None found	Phase 2/3	Thyroid Eye Disease (NCT05176639)	Immune-mediated disorders	Viridian Therapeutics, Inc.	Zenas Biopharma; miRagen (acquired Viridian, which had licensed asset from ImmunoGen)
BION-1301	Zigakibart	APRIL	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge-stabilization)	Phase 3	IgA nephropathy (NCT05852938)	Immune-mediated disorders	Novartis / Chinook Therapeutics, Inc.
MEDI5752	Volrustomig	PD-1, CTLA-4	Full-length antibody	Bispecific		IgG1	lambda, kappa	Unconjugated			Reduced effector functions	Phase 3	Cervical cancer (NCT06079671); Non-small cell lung cancer (NCT05984277)	Cancer	AstraZeneca
MCLA-128	Zenocutuzumab	HER2, HER3	Full-length antibody	Bispecific	Humanized	IgG1	kappa	Unconjugated			L351K, T366K (heterodimerization)	Phase 2 (pivotal)	Neuregulin 1 fusion (NRG1+) cancer (NCT02912949)	Cancer	Merus N.V.
AGEN1181	Botensilimab	CTLA-4	Full-length antibody	Bispecific	Human	IgG1	kappa	Unconjugated			S239D, A330L, I332E (enhanced effector function)	Phase 2 (pivotal)	Colorectal cancer (NCT05608044)	Cancer	Agenus Inc.
L19-IL2, L19-TNF	Bifikafusp alfa, Onfekafusp alfa	Fibronectin extra-domain B	scFv fused with IL-2, scFv fused with TNF	Mixture of 2 monospecific antibodies	Human		kappa	Immunocytokine		IL-2, TNF		Phase 3	Melanoma (NCT03567889, NCT02938299)	Cancer	Philogen S.p.A.
Genakumab (not WHO assigned INN)		IL-1beta	Full-length antibody	Monospecific				Unconjugated				Phase 3	Gout (NCT05983445)	Inflammatory diseases	Changchun GeneScience Pharmaceutical Co., Ltd.
VYD222		SARS-CoV-2	Full-length antibody	Monospecific	Human	IgG1		Unconjugated			Half-life extension	Phase 3	COVID-19 (NCT06039449)	Infectious disease	Invivyd, Inc.
IMC-F106C		CD3, PRAME	scFV fused with TCR	Bispecific				Immunoconjugate		T cell receptor		Phase 3 pending	Melanoma (NCT06112314)	Cancer	Immunocore Ltd
JMT101	Becotatug	EGFR	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated				Phase 2 (pivotal)	Non-small cell lung cancer (CTR20212469)	Cancer	CSPC Pharmaceutical Group Limited
GR1801		Rabies virus G protein	scFv-Fc-Fab	Bispecific	Human	IgG1		Unconjugated			None found	Phase 3	Rabies (NCT05846568)	Infectious disease	Genrix (Shanghai) Biopharmaceutical Co. Ltd.
BAT4406F		CD20	Full-length antibody	Monospecific				Unconjugated				Phase 2/3	Neuromyelitis optica spectrum disorder (CTR20231610)	Immune-mediated disorders	Bio-Thera Solutions Ltd.
MK-7240	Tulisokibart	VEGI	Full-length antibody	Monospecific	Humanized	IgG1	kappa	Unconjugated			L234A, L235A, P329A (impair Fc effector functions)	Phase 3	Ulcerative colitis (NCT06052059)	Immune-mediated disorders	Merck
BL-B01D1	Izalontamab brengitecan	EGFR, HER3	(Fab)2-Fc-(scFv)2	Bispecific		IgG1	kappa - [scFv - heavy - lambda]2	ADC	Cathepsin B (Cleavable linker)	Ed-04 (topoisomerase I inhibitor)		Phase 3	Nasopharyngeal carcinoma (NCT06118333 / CTR20233419)	Cancer	Sichuan Baili Pharmaceutical Co. Ltd	Systimmune
BAT1308		PD-1		Monospecific	Humanized	IgG4		Unconjugated				Phase 2/3 pending	Cervical cancer (NCT06123884 / CTR20232394)	Cancer	Bio-Thera Solutions Ltd.
SAR445229	Amlitelimab	OX40L	Full-length antibody	Monospecific	Human	IgG4	kappa	Unconjugated			S228P (hinge stabilization), L235E ( reduce effector function)	Phase 3	Atopic dermatitis (NCT06130566)	Immune-meditated disorders	Sanofi
AZD2936	Rilvegostomig	TIGIT, PD-1	Full-length antibody	Bispecific	Humanized	IgG1	lambda2, kappa	Unconjugated				Phase 3	Biliary tract cancer (NCT06109779)	Cancer	AstraZeneca	Compugen Ltd.
JS004, TAB004	Tifcemalimab	BTLA	Full-length antibody	Monospecific	Humanized	IgG4	kappa	Unconjugated			S228P (hinge stabilization)	Phase 3 pending	Small cell lung cancer (NCT06095583)	Cancer	Shanghai Junshi Bioscience Co Ltd
SAR441344, INX-021	Frexalimab	CD40L	Full-length antibody	Monospecific	Chimeric	IgG1	kappa	Unconjugated			V215A E269R K322A (enhanced effector functions)	Phase 3	Multiple sclerosis (NCT06141473, NCT06141486)	Immune-meditated disorders	Sanofi	ImmuNext
ALXN2220, NI006		Transthyretin amyloid	Full-length antibody	Monospecific	Humanized			Unconjugated				Phase 3	Transthyretin amyloid cardiomyopathy (NCT06183931)	Cardiovascular / hemostasis	AstraZeneca	Neurimmune AG
FG-M108, M108		Claudin-18.2	Full-length antibody	Monospecific				Unconjugated				Phase 3 pending	Gastric or gastroesophageal junction adenocarcinoma (NCT06177041)	Cancer	FutureGen Biopharmaceutical (Beijing) Co. Ltd
SSGJ-613		IL-1 beta	Full-length antibody	Monospecific	Humanized			Unconjugated				Phase 3 pending	Gout (NCT06169891)	Inflammatory diseases	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RZ358, XOMA 358		Insulin receptor	Full-length antibody	Monospecific	Human	IgG2		Unconjugated				Phase 3	Congenital hyperinsulinism	Metabolic disorders	Rezolute Inc	XOMA
9MW2821		Nectin-4	Full-length antibody	Monospecific	Humanized			ADC	Valine-Citrulline (Cleavable linker)	MMAE		Phase 3 pending	Urothelial carcinoma (CTR20234024)	Cancer	Mabwell (Shanghai) Bioscience Co. Ltd.

Table notes: in the “Backbone” column, the isotype refers to human unless indicated otherwise with the prefix m- (murine) or r- (rat).